reports
New Mountain Finance Corp: 1 director
A director at New Mountain Finance Corp bought 437,400 shares at 8.039USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...
Vera Therapeutics Appoints Christopher Hite to Board of Directors
Vera Therapeutics Appoints Christopher Hite to Board of Directors BRISBANE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Christopher Hite, an accomplished executive with decades of corporate and financial strategy leadership experience in the biopharmaceutical sector, to Vera Therapeutics’ Board of Directors. "It is a pleasure to welcome Chris to our Board of Directors at this...
- Jonathan Moreland
RUN SUNRUN INC.
PYPL PAYPAL HOLDINGS INC
NMFC NEW MOUNTAIN FINANCE CORPORATION
GPK GRAPHIC PACKAGING HOLDING COMPANY
FMNB FARMERS NATIONAL BANC CORP.
DIN DINE BRANDS GLOBAL INC.
ACIW ACI WORLDWIDE INC.
WD WALKER & DUNLOP INC.
TTEC TELETECH HOLDINGS
AXR INC.
PCB AMREP
TSLX PACIFIC CITY FINANCIAL CORP
FOUR SIXTH STREET SPECIALTY LENDING
THRY INC.
EOSE SHIFT4 PAYMENTS
LUNG INC.
AIRS THRYV HOLDINGS
TTD EOS ENERGY ENTERPRISES INC (A)
FBRT PULMONX
BLCO AIRSCULPT TECHNOLOGIES INC
GTE THE TRADE DESK
EDSA FRANKLIN BSP REALTY TRUST INC
LAW BAUSCH + LOMB CORP
PMN GRAN TIERRA ENERGY INC.
EDESA BIOTECH INC
CS DISCO INC
PROMIS NEUROSCIENCES INC.
Advanced Flower Capital Inc. Announces Financial Results for the Fourt...
Advanced Flower Capital Inc. Announces Financial Results for the Fourth Quarter and Full Year 2025 Fourth quarter 2025 GAAP net income of $0.9 million or $0.04 per basic weighted average common share and Distributable Earnings(1) of $(2.8) million or $(0.12) per basic weighted average common share Full year 2025 GAAP net loss of $(20.7) million or $(0.95) per basic weighted average common share and Distributable Earnings of $8.7 million or $0.39 per basic weighted average common share WEST PALM BEACH, Fla., March 04, 2026 (GLOBE NEWSWIRE) -- Advanced Flower Capital Inc. (Nasdaq: AFCG) (...
- Jonathan Moreland
ZBRA ZEBRA TECHNOLOGIES CORPORATION CLASS A
XRAY DENTSPLY SIRONA INC.
VNO VORNADO REALTY TRUST
TCBI TEXAS CAPITAL BANCSHARES INC.
NMFC NEW MOUNTAIN FINANCE CORPORATION
MTDR MATADOR RESOURCES COMPANY
FFIN FIRST FINANCIAL BANKSHARES INC
WD WALKER & DUNLOP INC.
AUP AURINIA PHARMACEUTICALS INC.
SABR SABRE CORP.
TREX TREX COMPANY INC.
AJG ARTHUR J. GALLAGHER & CO.
KKR KKR & CO. INC.
SMCI SUPER MICRO COMPUTER
AHCO INC.
DCTH ADAPTHEALTH
TSLX DELCATH SYSTEMS
THRY SIXTH STREET SPECIALTY LENDING
EOSE INC.
AGL THRYV HOLDINGS
FRSH EOS ENERGY ENTERPRISES INC (A)
FA AGILON HEALTH
CMTG INC.
MYN FRESHWORKS INC.
WRB FIRST ADVANTAGE CORP NEW
BLCO CLAROS MORTGAGE TRUST
NMTC INC.
MSDL BLACKROCK MUNIYELD N Y INSD FD INC
LAW W.R. BERKLEY CORPORATION
BAUSCH + LOMB CORP
NEUROONE MEDICAL TECHNOLOGIES CORP
MORGAN STANLEY DIRECT LENDING
CS DISCO INC
Chart Industries Reports Fourth Quarter and Full Year 2025 Financial R...
Chart Industries Reports Fourth Quarter and Full Year 2025 Financial Results HOUSTON, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Chart Industries, Inc. (NYSE: GTLS) today reported results for the fourth quarter and full year ended December 31, 2025. Full year 2025 compared to full year 2024: Orders of $5.68 billion increased 13.4%; full year 2025 book-to-bill of 1.33Sales of $4.26 billion increased 2.5%; sales increased 4.1% excluding a large lifecycle project and a large aftermarket equipment sale in 2024, which did not repeat in 2025Reported operating income of $358.4 million (8.4% of sales) o...
- Laura Chico
- Thomas Yip
Vera Therapeutics Provides Business Update and Reports Full Year 2025 ...
Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results Positive Phase 3 data from ORIGIN 3 study of atacicept in IgA nephropathy (IgAN) presented at American Society of Nephrology (ASN) Kidney Week and published in the New England Journal of MedicineU.S. Food and Drug Administration (FDA) granted priority review to Biologics License Application (BLA) for atacicept with Prescription Drug User Fee Act (PDUFA) date of July 7, 2026; potential commercial launch of atacicept expected in mid-2026Strong balance sheet bolstered by equity and debt financings in 2025 e...
Vera Therapeutics to Participate at Upcoming Investor Conferences
Vera Therapeutics to Participate at Upcoming Investor Conferences BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present and participate in one-on-one meetings at upcoming investor conferences. Investor Conference Details: TD Cowen 46th Annual Health Care ConferenceFormat: Fireside chat and 1x1 investor meetings Webcast: Date: ...
Tidewater Inc: 1 director
A director at Tidewater Inc sold 15,000 shares at 77.500USD and the significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
Beyond Air® Comments on Landmark Independent Review Article Highlighti...
Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections GARDEN CITY, N.Y., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today commented on the publication of an independent review article providing the most comprehensive overview to date of high‑d...
QCR Holdings, Inc. Announces Increased Cash Dividend of $0.10 Per Shar...
QCR Holdings, Inc. Announces Increased Cash Dividend of $0.10 Per Share MOLINE, Ill., Feb. 19, 2026 (GLOBE NEWSWIRE) -- QCR Holdings, Inc. (NASDAQ: QCRH) (the “Company”) today announced that on February 18, 2026, the Company’s Board of Directors declared a cash dividend of $0.10 per share payable on April 3, 2026, to stockholders of record on March 19, 2026. This dividend represents an increase from the prior quarterly dividend of $0.06 per share and reflects the Company’s strong financial performance, disciplined approach to capital management, and the Board’s confidence in the Company’...
Newtek Bank Receives Awards for Lending Capabilities and for Deposit A...
Newtek Bank Receives Awards for Lending Capabilities and for Deposit Accounts BOCA RATON, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: NEWT) is pleased that its bank subsidiary, Newtek Bank, N.A., (the “Bank”) was recently recognized for its lending capabilities and for its deposit account offering. The Coleman Report named Newtek Bank “.” The Coleman Report is a leading authority on loan programs of the U.S. Small Business Administration (SBA).NerdWallet honored Newtek Bank for having the “.” In determining the top savings account, NerdWallet evaluated more than 100...
Beyond Air® Reports Fiscal Third Quarter 2026 Financial Results and Pr...
Beyond Air® Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update Increased revenue by 105% year-over-year (YoY) to $2.2 million in fiscal Q3 Maintain fiscal year 2026 revenue guidance of $8-10 million $22.3 million pro forma cash, cash equivalents, restricted cash and marketable securities, including net proceeds from recent PIPE transaction, expected to provide runway into calendar 2027 Signed binding letter of intent for XTL Biopharmaceuticals to acquire 85% of Beyond Air's subsidiary NeuroNOS; Beyond Air to receive up to $32.5 million from the combinatio...
Piedmont Realty Trust, Inc. Releases Fourth Quarter and Annual 2025 Re...
Piedmont Realty Trust, Inc. Releases Fourth Quarter and Annual 2025 Results Atlanta, GA, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Piedmont Realty Trust (NYSE: PDM) has released its financial and operational results for the fourth quarter and year ended December 31, 2025. Please visit the Investor Relations section of Piedmont's website at to access the Earnings Release and Supplemental Information. Piedmont has scheduled a conference call and an audio web cast for Thursday, February 12, 2026, at 9:00 a.m. ET during which the Company’s management team will review fourth quarter and annual perf...
AFC Schedules Earnings Release and Conference Call for the Fourth Quar...
AFC Schedules Earnings Release and Conference Call for the Fourth Quarter and Full Year Ended December 31, 2025 WEST PALM BEACH, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- AFC today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2025, on Wednesday, March 4, 2026, before market open. Management will review AFC’s financial results at 10:00 am ET via webcast available on the Investor Relations section of AFC’s website found here . Participants are also invited to access the conference call by registering in advance at this . A repla...
AFC Commits $29 Million to a Senior Term Loan for a Sponsor Acquisitio...
AFC Commits $29 Million to a Senior Term Loan for a Sponsor Acquisition Supports the Acquisition and Growth of a Leading Healthcare Benefits Platform and Demonstrates AFC’s Expanded Investment Mandate as a BDC WEST PALM BEACH, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- AFC today announced that it has committed $29 million to a $60 million senior secured term loan. The proceeds from the credit facility, including $19.6 million funded by AFC at close, will be used to finance the acquisition of a leading healthcare benefits platform (the “Platform”). “We are excited to support a top-tier sp...
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rul...
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on February 2, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 11,500 shares of Class A common stock and restricted stock units (RSUs) underlying 5,750 shares of Class A common stock to two (2) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan...
AFC Provides $60 Million Senior Secured Credit Facility to Support the...
AFC Provides $60 Million Senior Secured Credit Facility to Support the Combination of STAT Recovery Services and The Moresby Group Facilitating Cambridge Capital’s Strategy to Create a Leading Revenue and Cost Optimization Platform WEST PALM BEACH, Fla., Feb. 05, 2026 (GLOBE NEWSWIRE) -- AFC today announced that its wholly owned subsidiary TCGDL LLC has closed a $60 million senior secured credit facility to STAT Buyer, LLC, a holding company controlled by Cambridge Capital (“Cambridge”), formed to facilitate the combination of its existing portfolio company STAT with The Moresby Group (...
Beyond Cancer Abstract Featuring Phase 1 Data on Intratumoral Ultra-Hi...
Beyond Cancer Abstract Featuring Phase 1 Data on Intratumoral Ultra-High Concentration Nitric Oxide (UNO) in Solid Tumor Metastases to be Presented at the AACR Annual Meeting 2026 GARDEN CITY, N.Y., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors and subsidiary of Beyond Air, Inc. (NASDAQ: XAIR), today announced being selected to present an abstract featuring data from the Phase 1 trial of intratumoral UNO in solid tumor metastases at the American A...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.